Covidien Sonicision Line Expands, 3 Devices Gain FDA Nod

Zacks Equity Research

Covidien plc (COV) recently announced the expansion of its Sonicision Cordless Ultrasonic Dissection Device portfolio, following the U.S. Food and Drug Administration (:FDA) clearance for three additional device lengths − 13 cm, 26 cm and 48 cm.

Covidien’s Sonicision system is a hand-held, pistol-grip style, battery-powered surgical ultrasonic device that is designed for soft-tissue incision and hemostasis. The device is used in a wide variety of surgical procedures, including general, bariatric, colorectal, gynecological and urological.

The newly-approved device lengths allow surgeons to expand their use of the Sonicision system to a more diverse range of surgical procedures, including pediatric colectomy, splenectomy, and appendectomy.

The Sonicision device’s cordless design allows complete freedom of movement to surgeons when applying ultrasonic energy. Increased mobility eliminates the need for managing cords in a sterile field and helps increase procedural efficiencies. In addition, reducing the number of cords and separate generators in the operating room contributes to a safer operating environment and patient experience.

Way back in Oct 2012, Covidien had unveiled Sonicision, the industry’s first cordless ultrasonic dissection device, at the American College of Surgeons Clinical Congress. The full cordless ultrasonic portfolio is currently available in the U.S.

With the most versatile cordless ultrasonic portfolio in the industry, Covidien now offers surgeons a wide range of options when performing pediatric, urological and bariatric procedures on patients of all sizes.

Covidien is focused on developing and delivering energy-based medical technologies. The Sonicision system’s innovative cordless offerings provide transformational options in the field of minimally invasive surgeries.

Currently, Covidien carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical products industry include ICU Medical (ICUI), Abaxis, Inc. (ABAX) and Eagle Pharmaceuticals (EGRX). ICU Medical sports a Zacks Rank #1 (Strong Buy), while both Abaxis and Eagle Pharmaceuticals carry a Zacks Rank #2 (Buy).

Read the Full Research Report on COV
Read the Full Research Report on ABAX
Read the Full Research Report on ICUI
Read the Full Research Report on EGRX


Zacks Investment Research